Video Reports

Source: OncLive, June 2019 Transcript: Ryan J. Sullivan, MD: Inhibiting BRAF-mutated melanoma typically is—we use 2 drugs. We use an inhibitor BRAF itself, targeting the oncogene specifically, and then we inhibit a…

Source: The Conversation, June 2019 Transcript: Hussein A. Tawbi, MD: The combination of BRAF and MEK inhibitors has been studied in actually 3 different combinations. So dabrafenib and trametinib was the…

Source: OncLive, June 2019 Transcript: Hussein A. Tawbi, MD: The COLUMBUS trial was a study that had a phase III component that randomized patients to encorafenib and binimetinib versus single-agent encorafenib…

Source: OncLive, June 2019 Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity…